APOBEC3G expression and HIV-1 infection in Burkina Faso

Tegwinde Rebeca Compaore; Serge Theophile Soubeiga; Abdoul Karim Ouattara; Damehan Tchelougou; Cyrille Bisseye; Didier Romuald Bakouan; Issaka Compaore; Augustine Dembele; Albert Theophane Yonli; Dorcas Obiri-Yeboah; Wendkuuni Florencia Djigma; Jacques Simpore

doi:10.4081/jphia.2018.907

APOBEC3G expression and HIV-1 infection in Burkina Faso

J Public Health Afr. 2018 Dec 21;9(3):907. doi: 10.4081/jphia.2018.907.

Affiliations

¹ Pietro Annigoni Biomolecular Research Centre (CERBA)/LABIOGENE, University of Ouagadougou, Burkina Faso.
² Permanent Secretary Against Aids and Sexually Transmitted Diseases, Ouagadougou, Burkina Faso.
³ Microbiology Department, School of Medical Sciences, University of Cape Coast, Ghana.

Abstract

APOBEC3G is a potent inhibitor of HIV-1 replication, and act by deaminating cytidines in uracil on the negative strand of the viral cDNA. In this case-control study, APOBEC3G expression in subjects' naïve to HAART infected by HIV-1 and the effect of APOBEC3G polymorphism on its expression were evaluated. The results show that the HIV-1 infected carriers of the G minor alleles of the variant rs8177832 had a higher expression of APOBEC3G mRNA than the controls carriers of the G minor allele. APOBEC3G polymorphisms could play an important role in the modulation of the HIV-1 dissemination.

Keywords: APOBEC3G mRNA; Burkina Faso; HIV-1; rs35228531; rs6001417; rs8177832.

Grants and funding

Funding: The Permanent Secretary for the fight against AIDS and STIs (CNLS/IST) of Burkina Faso; the WAEMU/PACER2 and the Pietro Annigoni Association.